The U.S. Food and Drug Administration announced to withdraw of Ranitidine HCl as N-Nitrosodimethylamine (NDMA) found as an impurity, which is a probable carcinogen. The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity.